Brii Biosciences Ltd
HKEX:2137
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Brii Biosciences Ltd
Tax Provision
Brii Biosciences Ltd
Tax Provision Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Tax Provision | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Brii Biosciences Ltd
HKEX:2137
|
Tax Provision
-¥1.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
Tax Provision
-¥1.1B
|
CAGR 3-Years
-74%
|
CAGR 5-Years
-48%
|
CAGR 10-Years
N/A
|
|
|
Innovent Biologics Inc
HKEX:1801
|
Tax Provision
-¥25.4m
|
CAGR 3-Years
-42%
|
CAGR 5-Years
29%
|
CAGR 10-Years
N/A
|
|
|
RemeGen Co Ltd
SSE:688331
|
Tax Provision
-¥748.7k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Akeso Inc
HKEX:9926
|
Tax Provision
¥0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
S
|
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
|
Tax Provision
-¥26.2m
|
CAGR 3-Years
19%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Brii Biosciences Ltd
Glance View
Brii Biosciences Ltd. is a holding company, which engages in the research and development of medicines. The company is headquartered in Beijing, Beijing and currently employs 113 full-time employees. The company went IPO on 2021-07-13. The Company’s products are applied in infectious diseases, such as hepatitis B virus (HBV), human immunodeficiency virus (HIV), multi-drug resistant (MDR) or extensive drug resistant (XDR) gram-negative infections, and other illnesses, such as the central nervous system (CNS) diseases, which have significant public health burdens. The firm is also developing therapies for COVID-19 and other diseases.
See Also
What is Brii Biosciences Ltd's Tax Provision?
Tax Provision
-1.9m
CNY
Based on the financial report for Dec 31, 2025, Brii Biosciences Ltd's Tax Provision amounts to -1.9m CNY.
